Pfizer - Grants for AI-Enabled COVID-19 Treatment Research 2026

Deadline: Jul 07, 2026

postdoctoral | masters

NULL (duration)

partially funded

Germany, Japan, Canada, Australia, Korea, and 3 others

To Apply

Please visit the application link below to apply.

Opportunity Overview

🌟 About the Opportunity

The Pfizer - Grants for AI-Enabled COVID-19 Treatment Research program focuses on leveraging AI-driven healthcare solutions to improve access to antiviral treatment, identify eligible high-risk patients, manage drug–drug interactions, and support evidence-based COVID-19 care.

💰 Benefits

Maximum funding available: Up to $500,000 USD per project.

✅ Eligibility Criteria

To be eligible for this grant, applicants must meet the following requirements:

The institution and Principal Investigator (PI) must be based in one of the eligible countries: Australia, Canada, China, Germany, Greece, Japan, Korea, Taiwan.
Only organizations are eligible to receive grants, not individuals or medical practice groups (e.g., independent groups of physicians not affiliated with a hospital, academic institution, or professional society).
If the project involves multiple departments or institutions, all must have a relevant role, and the requesting organization must play a key role in the project.
The PI must hold one of the following degrees:
- Medical or postdoctoral degree (MD, PhD, or equivalent)
- Advanced nursing degree (BSN with a MS/PhD)
- Degree in Pharmacy, Physiotherapy, or Social Work
The applicant must be the PI or an authorized designee (e.g., PI’s research coordinator).
The PI must be an employee or contractor of the requesting organization.
The requesting organization must be legally able to receive award funding directly from Pfizer Inc. Applicants are strongly encouraged to confirm this with their organization prior to submitting an application.
Grants awarded to organizations unable to accept funding directly from Pfizer Inc. may be subject to rescission.